AF in Cancer Patients: A Different Need for Anticoagulation?

Cancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ana Pardo Sanz, José Luis Zamorano Gómez
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2019
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/d917cf8638154e9aabb6116bbb7aaa9d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d917cf8638154e9aabb6116bbb7aaa9d
record_format	dspace
spelling	oai:doaj.org-article:d917cf8638154e9aabb6116bbb7aaa9d2021-12-04T16:01:23ZAF in Cancer Patients: A Different Need for Anticoagulation?10.15420/ecr.2018.32.21758-37641758-3756https://doaj.org/article/d917cf8638154e9aabb6116bbb7aaa9d2019-01-01T00:00:00Zhttps://www.ecrjournal.com/articles/af-cancer-patients-different-need-anticoagulationhttps://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Cancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology patients. The balance between thromboembolic and bleeding risks of AF in these patients is particularly challenging. Little is known about whether embolic and bleeding risk scores used for the general population can be applied in oncologic patients. Cardiology involvement in the management of these patients seems to be associated with favourable AF-related outcomes.Ana Pardo SanzJosé Luis Zamorano GómezRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 14, Iss 1, Pp 65-67 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Ana Pardo Sanz José Luis Zamorano Gómez AF in Cancer Patients: A Different Need for Anticoagulation?
description	Cancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology patients. The balance between thromboembolic and bleeding risks of AF in these patients is particularly challenging. Little is known about whether embolic and bleeding risk scores used for the general population can be applied in oncologic patients. Cardiology involvement in the management of these patients seems to be associated with favourable AF-related outcomes.
format	article
author	Ana Pardo Sanz José Luis Zamorano Gómez
author_facet	Ana Pardo Sanz José Luis Zamorano Gómez
author_sort	Ana Pardo Sanz
title	AF in Cancer Patients: A Different Need for Anticoagulation?
title_short	AF in Cancer Patients: A Different Need for Anticoagulation?
title_full	AF in Cancer Patients: A Different Need for Anticoagulation?
title_fullStr	AF in Cancer Patients: A Different Need for Anticoagulation?
title_full_unstemmed	AF in Cancer Patients: A Different Need for Anticoagulation?
title_sort	af in cancer patients: a different need for anticoagulation?
publisher	Radcliffe Medical Media
publishDate	2019
url	https://doaj.org/article/d917cf8638154e9aabb6116bbb7aaa9d
work_keys_str_mv	AT anapardosanz afincancerpatientsadifferentneedforanticoagulation AT joseluiszamoranogomez afincancerpatientsadifferentneedforanticoagulation
_version_	1718372822427893760

AF in Cancer Patients: A Different Need for Anticoagulation?

Ejemplares similares